CSPC Pharmaceutical Group: Revenue, licensing income and pipeline milestones advanced alongside a 73.6% 1-9M gross marginQuartr·Nov 18, 2026 at 06:51 AM01093+1.20%
CSPC Reports Nine-Month Revenue and Profit Growth in 2026Tip Ranks·Nov 18, 2026 at 04:38 AM01093+1.20%
CSPC Pharmaceutical Group: AstraZeneca licence income and finished-drug growth lifted 9M revenue 27% and profit 101.5%Quartr·Nov 18, 2026 at 04:14 AM01093+1.20%
CSPC Initiates China Trial of SYH2051 Combination TherapyTip Ranks·Nov 16, 2026 at 10:40 AM01093+1.20%
Weekly Recap | CSPC PHARMA -4.74%, a pullback on light volumeWeekly Review·Nov 14, 2026 at 05:02 AM01093+1.20%
CSPC PHARMA Launches First Research Centers in China for Two Clinical TrialsAASTOCKS News·Nov 9, 2026 at 02:16 AM01093+1.20%
Weekly Recap | 1093.HK +7.03%, pipeline initiations stack upWeekly Review·Nov 7, 2026 at 05:21 AM01093+1.20%
CSPC Starts Phase I/II Trial of SYS6055 for B-Cell Non-Hodgkin Lymphoma in ChinaPUBT·Nov 6, 2026 at 11:10 AM01093+1.20%
CSPC Pharmaceutical Schedules Board Meeting to Approve Nine-Month ResultsPUBT·Nov 6, 2026 at 11:04 AM01093+1.20%
CSPC Pharmaceutical starts Phase I/II trial of SYS6062 for advanced solid tumors in ChinaPUBT·Nov 5, 2026 at 10:25 AM01093+1.20%
CSPC Pharmaceutical Starts Phase II Trial of SYH2072 for Hypertension in ChinaPUBT·Nov 3, 2026 at 10:26 AM01093+1.20%